{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:34:59Z","timestamp":1771054499862,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001296","type":"journal-article","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:16:04Z","timestamp":1069384564000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Aspirin for vascular dementia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Gianetta","family":"Rands","sequence":"first","affiliation":[{"name":"Camden and Islington NHS Foundation Trust; Highgate Mental Health Centre; Dartmouth Park Hill London UK N19 5NX"},{"name":"University College London; Mental Health Sciences Unit; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Orrell","sequence":"additional","affiliation":[{"name":"University College London; Mental Health Sciences Unit; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2000,10,23]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD001296-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1474-4422(07)70293-4","article-title":"Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial","volume":"7","author":"Bentham","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD001296-BIB0002|cit2","unstructured":"Anon Aspirin for the prevention of cognitive decline in the Elderly: a Neuro-Vascular Imaging Study (ENVIS-ion), a sub-study of ASPirin in Reducing Events in the Elderly (ASPREE); [Official title] A multi-centre, randomised, double-blind, placebo controlled trial of the effects of 100mg enteric-coated aspirin on rate of increase of magnetic resonance imaging (MRI)-based white matter hyperintensity (WMH) and silent brain infarction (SBI), 2008. www.mrw.interscience.wiley.com\/cochrane\/clcentral\/articles\/617\/CN-00724617\/frame.html (accessed 20 August 2012)"},{"issue":"11","key":"10.1002\/14651858.CD001296-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archneur.57.11.1586","article-title":"Anti-inflammatory drugs protect against Alzheimer's disease at low doses","volume":"57","author":"Broe","year":"2000","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001296-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.01.012","article-title":"Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial","volume":"20","author":"Guekht","year":"2011","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD001296-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<926::AID-GPS665>3.0.CO;2-Y","article-title":"Aspirin, Anti-inflammatory drugs and risk of dementia","volume":"12","author":"Henderson","year":"1997","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001296-BIB0007|cit6","first-page":"148","article-title":"Controlled clinical trial of daily aspirin therapy in multi-infarct dementia","volume":"19","author":"Meyer","year":"1988","journal-title":"Stroke"},{"issue":"6","key":"10.1002\/14651858.CD001296-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1532-5415.1989.tb05688.x","article-title":"Randomized clinical trial of daily aspirin therapy in multi-infarct dementia: a pilot study","volume":"37","author":"Meyer","year":"1989","journal-title":"Journal of the American Geriatrics Society"},{"issue":"4","key":"10.1002\/14651858.CD001296-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1368-5031.2004.00127.x","article-title":"Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open 16 month, comparative study","volume":"58","author":"Moretti","year":"2004","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD001296-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"a1198","DOI":"10.1136\/bmj.a1198","article-title":"Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial","volume":"337","author":"Price","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD001296-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/STROKEAHA.109.571281","article-title":"Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study","volume":"41","author":"Richard","year":"2010","journal-title":"Stroke"},{"issue":"7","key":"10.1002\/14651858.CD001296-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/oxfordjournals.aje.a008801","article-title":"Aspirin use and cognitive function in the elderly","volume":"143","author":"Sturmer","year":"1996","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD001296-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000284596.95156.48","article-title":"NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type","volume":"70","author":"Szekely","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001296-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ahj.2009.11.030","article-title":"Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP) - a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events","volume":"159","author":"Teramoto","year":"2010","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD001296-BIB0014|cit14","unstructured":"Thoonsen H Richard E Bentham P Gray R De Haan RJ Van Gool WA Aspirin in Alzheimer's disease: increased risk of intracerebral haemorrhage - cause for concern? Cerebrovascular Diseases.\u00a0Proceedings of the 19th European Stroke Conference; 201 May 25-28; Barcelona Basal Karger 2010"},{"key":"10.1002\/14651858.CD001296-BIB0015|cit15","unstructured":"Yining H (principal investigator) Cilostazol versus aspirin for vascular dementia in poststroke patients with white matter lesions (CAVAD). clinicaltrials.gov\/ct2\/show\/NCT00847860, 2011 (accessed 20 August 2012)"},{"issue":"2","key":"10.1002\/14651858.CD001296-BIB0016|cit16","first-page":"73","article-title":"Efficacy observation of batroxobin for treatment of vascular cognitive impairment","volume":"7","author":"Zhai","year":"2010","journal-title":"Chinese Journal of Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD001296-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative Overview of trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001296-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/pb.22.5.285","article-title":"Management of cognitive impairment of vascular origin","volume":"22","author":"Dennis","year":"1998","journal-title":"Psychiatric Bulletin: The Journal of Trends in Psychiatric Practice"},{"key":"10.1002\/14651858.CD001296-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/gps.857","article-title":"Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis","volume":"18","author":"Devine","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001296-BIB0020|cit20","volume-title":"International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for\u00a02010","author":"World Health Organization","year":"2010"},{"issue":"4","key":"10.1002\/14651858.CD001296-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1017\/S0317167100034351","article-title":"Subcortical vascular dementia: survey of treatment patterns and research considerations","volume":"25","author":"Molnar","year":"1998","journal-title":"Canadian Journal Of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD001296-BIB0022|cit22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001296","article-title":"Aspirin for vascular dementia","author":"Rands","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001296\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T16:08:55Z","timestamp":1725466135000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001296"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2000,10,23]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001296","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10,23]]}}}